TAK-659 hydrochloride
CAS No. 1952251-28-3
TAK-659 hydrochloride( Mivavotinib | TAK 659 | TAK659 )
Catalog No. M13056 CAS No. 1952251-28-3
TAK-659 hydrochloride (Mivavotinib, TAK659) is a potent, selective and orally available SYK inhibitor with IC50 of 3.2 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 68 | In Stock |
|
| 10MG | 102 | In Stock |
|
| 25MG | 205 | In Stock |
|
| 50MG | 312 | In Stock |
|
| 100MG | 484 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTAK-659 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionTAK-659 hydrochloride (Mivavotinib, TAK659) is a potent, selective and orally available SYK inhibitor with IC50 of 3.2 nM.
-
DescriptionTAK-659 hydrochloride (Mivavotinib, TAK659) is a potent, selective and orally available SYK inhibitor with IC50 of 3.2 nM; displays 36, 42 and 23-fold selectivity over JAK3, ZAP70 and VEGFR2, respectively; also potently inhibits FLT-3; inhibits cellular proliferation in SYK-dependent DLBCL and FLT3-dependent AML cell lines, demonstrates potent tumor growth inhibition in the FLT3-dependent MV4-11 xenograft models.Blood Cancer Phase 2 Clinical(In Vitro):TAK-659 hydrochloride inhibits cellular proliferation in SYK-dependent DLBCL and FLT3-dependent AML cell lines.TAK-659 hydrochloride (5 μM; 1-24 hours) induces Casp3 activation in the LMP2A/MYC cells which was readily apparent at 4 h and reached maximum levels at 8 h of treatment.TAK-659 hydrochloride (0.01-10 μM; 1 hour) stimulates expression of phospho-Syk at Tyr525 and Tyr352 and phospho-ERK1/2 increased in Ramos cells.(In Vivo):TAK-659 hydrochloride (100 mg/kg/day; p.o.; daily, for 10 days) treatment totally abrogates splenomegaly and tumor development in LMP2A/MYC mice in both pretumor and tumor cell transfer experiments.TAK-659 hydrochloride treatment kills tumor cells, but not host cells within the spleen and tumors.TAK-659 hydrochloride treatment abrogates metastasis of tumor cells into bone marrow.
-
In VitroTAK-659 hydrochloride inhibits cellular proliferation in SYK-dependent DLBCL and FLT3-dependent AML cell lines.TAK-659 hydrochloride (5 μM; 1-24 hours) induces Casp3 activation in the LMP2A/MYC cells which was readily apparent at 4 h and reached maximum levels at 8 h of treatment.TAK-659 hydrochloride (0.01-10 μM; 1 hour) stimulates expression of phospho-Syk at Tyr525 and Tyr352 and phospho-ERK1/2 increased in Ramos cells. Apoptosis Analysis Cell Line:LMP2A/MYC cells Concentration:5 μM Incubation Time:1 hour, 2 hours, 4 hours, 8 hours, 24 hours Result:Induced apoptosis in LMP2A/MYC lymphoma cells.Western Blot Analysis Cell Line: Ramos cells Concentration: 0.01 μM,0.1 μM,1 μM,10 μM Incubation Time:1 hour Result:Enhanced expression of phospho-Syk at Tyr525 and Tyr352 and phospho-ERK1/2 in stimulated Ramos cells.
-
In VivoTAK-659 hydrochloride (100 mg/kg/day; p.o.; daily, for 10 days) treatment totally abrogates splenomegaly and tumor development in LMP2A/MYC mice in both pretumor and tumor cell transfer experiments.TAK-659 hydrochloride treatment kills tumor cells, but not host cells within the spleen and tumors.TAK-659 hydrochloride treatment abrogates metastasis of tumor cells into bone marrow. Animal Model:LMP2A/MYC double transgenic mice Dosage:100 mg/kg/day Administration:Oral gavage; for 10 daysResult:Inhibited LMP2A-induced tumor cell survival in vivo.
-
SynonymsMivavotinib | TAK 659 | TAK659
-
PathwayAngiogenesis
-
TargetSyk
-
RecptorFLT3|JAK3|Syk|VEGFR2|ZAP70
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1952251-28-3
-
Formula Weight380.852
-
Molecular FormulaC17H22ClFN6O
-
Purity>98% (HPLC)
-
SolubilityDMSO: <1 mg/mL; Ethanol: <1 mg/mL; Water: 4 mg/mL (10.5 mM), warmed ( < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESCN1C=C(C=N1)C2=NC(=C(C3=C2C(=O)NC3)F)NC4CCCCC4N.Cl
-
Chemical Name6-(((1R,2S)-2-aminocyclohexyl)amino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one hydrochloride
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lam B, et al. Bioorg Med Chem Lett. 2016 Dec 15;26(24):5947-5950.
2. Purroy N, et al. Oncotarget. 2017 Jan 3;8(1):742-756.
molnova catalog
related products
-
Cis-ACBD
2, 4-methanoglutamate is a potent and selective N-methyl-D-aspartate receptor agonist.
-
TAK-659
TAK-659 (TAK659, Mivavotinib) is a potent, selective and orally available SYK inhibitor with IC50 of 3.2 nM.
-
R788 disodium hexahy...
Fostamatinib (R788) is a prodrug of the active metabolite R406, which is a potent, ATP-competitive inhibitor of Syk kinase with Ki/IC50 of 30/41 nM.
Cart
sales@molnova.com